SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending amid widespread discussion and conflicting reports regarding a major deal with AI chip startup Groq, debated as either a $20 billion acquisition or a strategic licensing agreement. The community is sharply divided, with bulls touting it as a genius move to solidify NVIDIA's dominance in AI inference and talent acquisition, while bears decry it as a desperate, overpriced gambit. This strategic play aims to further cement NVIDIA's leadership across the entire AI hardware lifecycle, from training to the increasingly crucial inference market.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as community sentiment is fueled by technical indicators like anticipated "golden crosses" and calls for a significant breakout. Recent reports of users moving their coins to self-custody wallets due to security concerns and exchange transfer issues are also driving conversation. While many expect a rally for the "digital silver," others remain skeptical of its current performance.

Ethereum Classic

Ethereum Classic ($ETC) is trending amidst intense community debate, fueled by recent price volatility and its surprising appearance as a top trending asset. Many long-term holders express deep frustration over its sustained underperformance compared to other major cryptocurrencies, while a segment of the community remains strongly bullish, viewing current price levels as a significant discount and a "loading zone" before an anticipated breakout.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs and upcoming Chinese export restrictions. This rally is further fueled by booming industrial demand from EV batteries, solar, and AI data centers, sparking community debate over a potential 'silver squeeze' versus an impending sharp pullback.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the significant FDA approval of YARTEMLEA, making it the first and only approved treatment for a life-threatening post-transplant complication in both adults and children. The community is actively discussing the drug's blockbuster potential due to its lack of competition and the company's validated pipeline, alongside hopes for a short squeeze and potential buyout speculation, particularly from existing partner Novo Nordisk. Excitement is building ahead of the upcoming conference call where further details, including pricing, are anticipated.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following recent analyst upgrades and price target increases, with its CEO's media appearances highlighting key partnerships like OpenTable and potential future announcements at CES 2026. The community is engaged in a polarized discussion, weighing the company's "Agentic AI" technology, robust revenue growth, and zero-debt status against persistent short interest and recent price underperformance. Despite the division, many foresee significant long-term growth as the company expands its voice AI solutions across various sectors.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is a major trending topic as significant options expirations are driving notable short-term volatility and ongoing price debate. The community remains divided, with many bulls anticipating a strong breakout and long-term institutional accumulation once expiration pressure subsides, while bears highlight persistent selling pressure and perceived market manipulation.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is a focal point of conversation as investors anticipate its substantial monthly dividend, with many actively buying on recent dips and viewing current volatility as an accumulation opportunity. The community widely discusses the ETF's dividend payout in relation to its price movements around the ex-dividend date, while maintaining a long-term bullish outlook on Bitcoin's potential for future highs amid ongoing institutional adoption.

Boundless is a universal protocol that brings ZK to every chain. Using Boundless, developers can create expressive, high-throughput applications that bypass traditional block size/gas limits.  Developers submit proof requests and provers compete to fulfill them, earning direct rewards and protocol-level incentives through proof of verifiable work.  By abstracting away the complexity of proof generation, aggregation, and onchain settlement, Boundless allows developers to build without worrying about underlying infrastructure, while provers provide strong liveness guarantees, censorship-resistance, and continuously improve the cost curve driven by open market dynamics.  This architecture decouples execution from consensus and introduces a new paradigm for verifiable computing. As the number of Boundless prover nodes grows, the total capacity of the protocol increases, scaling compute across every chain.

Boundless

ZKC is trending due to its recently launched mainnet, positioning it as a key Ethereum scaling solution aiming to capture market share from competitors. The community is actively discussing its potential for a major reversal and breakout, while simultaneously debating concerns over recent price action and perceived lack of sustained volume.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

The Defiance Daily Target 2X Long SMCI ETF ($SMCX) is trending amid strong bullish sentiment for its underlying asset, Super Micro Computer ($SMCI), driven by positive news like Nvidia's China chip shipments and significant AI infrastructure investments. Traders are actively debating its extreme volatility and decay concerns, with many viewing current price levels as a "buy the dip" opportunity for substantial gains as they anticipate an AI sector rally.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026

MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors

What is HC Wainwright's Estimate for Ocugen FY2025 Earnings?

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings estimates for shares of Ocugen in a research note issued on Thursday, November 6th. HC Wainwright...

Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. $OCGN

Y Intercept Hong Kong Ltd purchased a new stake in shares of Ocugen, Inc. (NASDAQ:OCGN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange...

Ocugen (NASDAQ:OCGN) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Ocugen (NASDAQ:OCGN - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The firm...

Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -16.67% and +46.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know

Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

Shares of Ocugen, Inc. (OCGN) rose 3% on Friday morning after the company reported a better-than-feared first-quarter (Q1) loss.The biotechnology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-provides-business-update-first-quarter-2025-financial">reported</a> a revenue of $1.5 million, up from $1 million in the corresponding quarter of 2024.Loss per share came in at $0.05, unchanged from the corresponding quarter of 2024, and better than the estimated loss of $0.06 per share.The company, which is developing gene therapies for blindness diseases, ended the quarter with cash and restricted cash totaling $38.1 million, compared to $58.8 million as of Dec. 31, 2024. It expects this will provide runway into the first quarter of 2026.CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the U.S. Food and Drug Administration (FDA) requesting approval for the distribution of three of its products in the next three years.“We remain steadfast in our mission to provide a one-time therapy for life to address considerable unmet medical needs that exist for millions of patients facing the terrifying prospect of losing their vision," he said.On Stocktwits, retail sentiment around Ocugen jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume stayed at high levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_9_57_35_AM_png_0d026d6926.webp" alt="Screenshot 2025-05-09 at 9.57.35 AM.png" width="630" height="63"><figcaption>OCGN's Sentiment Meter and Message Volume as of 9:24 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism for the stock, citing the three upcoming FDA applications.<stembedurl>https://stocktwits.com/FannyChmelar/message/614075330</stembedurl>Another noted that the low cash reserve is expected in a company not selling products yet.<stembedurl>https://stocktwits.com/Slapshot22/message/614070848</stembedurl><a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> is down by 21% this year and 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-faces-moltiply-lawsuit/chiWtc6RblO">Google Faces $3.3B Lawsuit From Italy’s Moltiply Group: Search Giant Disagrees With ‘Exorbitant’ Private Damages Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.

Equity

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.


Ocugen, Inc.'s stock dropped 2.8% during Wednesday's session but bounced back in extended trading after the company posted a quarterly earnings report that exceeded revenue expectations.The biopharmaceutical company, which focuses on developing gene therapies for eye diseases, reported a fourth-quarter loss of $0.05 per share, in line with estimates.&nbsp;Revenue was $764,000, down from $1.4 million a year ago due to reduced co-development services, but still well above the $400,000 analysts expected.Ocugen's modifier gene therapy platform includes OCU400, OCU410, and OCU410ST, which target inherited retinal diseases (IRDs) and conditions like dry age-related macular degeneration (dAMD) and Stargardt disease.Its OCU400 is in Phase 3 clinical trials for retinitis pigmentosa (RP) in the U.S. and Canada, with enrollment expected to be completed in the first half of 2025.OCU500, Ocugen's inhaled mucosal COVID-19 vaccine, recently received FDA clearance for an Investigational New Drug (IND) application.&nbsp;The National Institute of Allergy and Infectious Diseases (NIAID) will sponsor a Phase 1 trial evaluating two delivery routes — lung inhalation and nasal spray.To extend its cash runway into the first quarter of 2026 and support ongoing clinical trials, Ocugen secured $65 million in equity and debt financing in the second half of 2024.&nbsp;In May, the company was included in the Russell Index.On Stocktwits, sentiment for Ocugen ended Wednesday higher within the 'bullish' zone, with message volume surging 32%.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/OCGN_sentiment_and_message_volume_as_of_March_5_42ff8160da.png" alt="OCGN sentiment and message volume as of March 5.png" width="1316" height="302"><figcaption>OCGN sentiment and message volume as of March 5 | source: Stocktwits</figcaption></figure>One retail trader said the value of Ocugen's pipeline "is insane and I'll be holding when it comes to fruition."<stembedurl>https://stocktwits.com/SGimvesting/message/606846472</stembedurl>Another was hopeful after pointing out that CEO Shankar Musunuri confirmed NIAID's funding support for OCU500's Phase 1 trial next quarter.<stembedurl>https://stocktwits.com/Hamiltoes/message/606856276</stembedurl>Ocugen's ambitious roadmap targets three potential Biologics License Applications (BLAs) between 2026 and 2028, covering RP, Stargardt, and geographic atrophy (GA).However, Ocugen faces a significant short interest rate of 20.7%, according to Koyfin data.&nbsp;The stock trades 1,033% below the average analyst price target of $6.50, with two analysts rating it a 'buy' and two a 'strong buy.'Shares of Ocugen are down over 33% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates

Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Current Price	$1.44
Prev Close	$1.40
Open	$1.43
Dividend Yield	0.00%
50-Day Moving Average	$1.36
Beta	1.70
Avg. Volume	3.39M
PE Ratio	-6.65

52-Week High	$1.90
52-Week Low	$0.515
Market Capitalization	$449.92M
EPS (Annual)	-$0.1993
Price to Book	127.32
Revenue Per Employee	$42,684.21
Enterprise Value/EBITDA	N/A

OCGN
Ocugen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OCGN News

OCGNOcugen Inc